Kornimate/medical-research-clean huggingface dataset:
the effect of transjugular intraheptic portosystemic shunt (tips) on gastrointestinal motility and the gut microbiota

Conditions: Cirrhosis

Summary: the effect of portal hypertension on gastrointestinal motility, and how reversal or improvement in portal hypertension may alter gastrointestinal motility, remains unclear and further research is needed. additionally, patients with cirrhosis have altered gut microflora, particularly rich in lactobacilli, including enterococci and bifidobacteria. transjugular intraheptic portosystemic shunting (tips) is a procedure performed by interventional radiologists, in which a connection is made between the portal and venous circulations, allowing high pressure portal blood to more easily enter the systemic circulation and bypass the liver; thus effectively decreased portal pressure.


Eligibility criteria:
inclusion criteria: * patients with either radiographic or biopsy proven decompensated cirrhosis (as determined by ascites, variceal hemorrhage, encephalopathy or jaundice). * patients undergoing an elective tips for any standard of care established indication (examples: worsening ascites, recurrent variceal bleeding). exclusion criteria: * pregnant women. * patients unwilling or unable to provide informed consent. * patients undergoing an emergent tips for acute or subacute variceal hemorrhage. * patients with diabetes, significant cardiovascular, renal or other chronic disease which has been known to affect intestinal motility. * previously diagnosed gastroparesis or other gi dysmotility disorder. * patients currently taking narcotics, antibiotics excluding rifaximin, prokinetic medications or lactulose. * patients with a history of gastric bezoar. * patients with a history of multiple intestinal surgeries or gi surgery within the past 3 months. * patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction. * patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction. * patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction. * patients with a history of diverticulitis. * patients with swallowing disorders and increased risk of aspiration (such as prior history of aspiration). * patient with celiac disease. * patients with implanted or portable electro-mechanical medical devices.

Keywords: gut microflora transjugular intraheptic portosystemic shunting
treatment with hepatic arterial infusion of oxaliplatin in combination with systemic folfiri chemotherapy and bevacuzimab in patients with liver-only colorectal liver metastases (crlm): conversion to complete resection in patients with initially inoperable liver-only crlm.

Conditions: Liver Metastasis Colon Cancer

Summary: a few studies have documented that some patients can be down-staged from an initially inoperable state to a potentially resectable state. five-year survival in initially inoperable patients that ultimately come to a complete resection appears to be similar to patients who are resected at first presentation. the investigators goal is to assess the rate of conversion to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with hai of oxaliplatin with folfiri and bevacuzimab systemic treatment.


Eligibility criteria:
subject inclusion criteria: * histologically confirmed colorectal adenocarcinoma metastatic to the liver. * the patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. * a patient may have had prior chemotherapy or be previously untreated. * ecog ps \<2 subject exclusion criteria: * prior radiation, hepatic thermo ablation or resection (other than biopsy) to the liver. * patient may not have received prior treatment with hepatic artery infusion (hai). * extrahepatic metastases * female patients who are pregnant or lactating
the georgia latino aids/hiv diagnosis and linkage in youth (gladly) project

Conditions: HIV

Summary: this study aims to understand the barriers to receiving hiv testing and retention of care for at risk and hiv positive young adults. this study also seeks to determine the feasibility and acceptability of hiv testing in a non-clinical setting.

this study aims to identify factors that can facilitate or impede the use of non-clinical hiv testing venues as well as identify potential testing sites and assess acceptability of an hiv prevention intervention. in addition, the study will implement a pilot intervention to test the feasibility non-clinical hiv testing and follow up events for hiv positive youth.

Eligibility criteria:
inclusion criteria: * sexually active * hiv positive or negative * latino youth ages 18-24 years * residents of the state of georgia and can understand spoken and written english or spanish. exclusion criteria: * unmet inclusion criteria

Keywords: aids health promotion
urinary retention following tatme vs latme total mesorectal excision for rectal cancer

Conditions: Rectal Cancer

Summary: a comprehensive study with prospectively collected data. these patients were assigned to either the tatme group or the latme group according to the surgery procedure received

transanal total mesorectal excision has emerged as a potential solution to certain limitations associated with laparoscopic total mesorectal excision in rectal cancer patients. differences in surgical approaches have raised questions regarding their impact on the risk of postoperative urinary retention, with limited data available from large scale study.

Eligibility criteria:
inclusion criteria: * age range from 18 to 65 years, * diagnosed with rectal cancer at clinical tumor node metastasis stages ii or iii. * palpable tumor determined by digital rectal examination or proctoscopy * the distal border of the tumor located within 12 cm from the anal verge exclusion criteria: * patients presenting clear indications of pelvic side wall involvement or distant metastasis * uncontrolled hypertension or cardiovascular disease * patients with synchronous colon cancer * history of other malignancies within the past 5 years

Keywords: urinary retention
parent training and emotion coaching for children with limited prosocial emotions

Conditions: Oppositional Defiant Disorder

Summary: the proposed research will focus on the development of a brief emotion-coaching (ec) parenting program (which directly targets child emotion awareness/recognition and affective empathy), that will be combined with a well-established parent management training program (helping the noncompliant child; hnc) for treating oppositional defiant disorder (odd) in children who also have limited prosocial emotions (e.g., lack of guilt and empathy, callous use of others).


Eligibility criteria:
inclusion criteria: * child with oppositional defiant disorder and low prosocial emotions exclusion criteria: * unable to speak/understand english * significant developmental delay or autism spectrum disorder

Keywords: children with odd and low prosocial emotions
role of pregabalin to decrease postoperative pain in microdiscectomy

Conditions: Pain, Nerve; Prolapsed Intervertebral Disc

Summary: the purpose of this study is to compare the effect of pregabalin in reducing the neuropathic pain in postoperative patients who have undergone single level microdiscectomy for prolapsed intervetebral lumbar disc.

all patients were informed in detailed regarding the risk and complications and given written and informed consent, coming to our clinics were assessed by one of the senior team members of the spine, patient fulfilling the eligibility criteria were selected and included in the study. one week before the surgery the patients who met the eligibility criteria were randomized in a double-blind manner (participant and investigator) in a ratio of 1:1 into group-a (pregabalin 7mg, twice daily) or group-b (placebo, twice daily). the pain scores were recorded by vas and roland morris score system on preoperative day compared to the scores on the 1st week postoperative follow-up.

Eligibility criteria:
inclusion criteria: * all patients with severe clbp and/or leg pain * patients with static or dynamic leg pain * patients with leg pain resulting from localized lumbar or lumbosacral segmental instability * spinal stenosis at levels l2-s1 or caused by isthmic spondylolisthesis (grade i and ii) exclusion criteria: * patients with previous lumbar surgery * patients allergic to gabapentinoids * patients with renal impairments * patients who are already on opioids, benzodiazepines, barbiturates, ethanol (alcohol) * patient presented with diabetes and other drugs that depress the central nervous system * patients who are already on ace inhibitors as they may enhance the adverse/toxic effect of pregabalin.

Keywords: microdiscectomy pregabalin
monoclonal antibody therapy in treating patients with stage iv melanoma

Conditions: Melanoma (Skin)

Summary: rationale: monoclonal antibodies can block tumor growth in different ways. some block the ability of tumor cells to grow and spread. others find tumor cells and help kill them or carry tumor-killing substances to them. purpose: this clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage iv melanoma.

objectives: primary * determine the safety/toxicity of a single dose of b7-dendritic cell cross-linking antibody containing plasma in treating patients with stage iv melanoma. secondary * describe the immunological changes (th1/th2 balance, frequency of tumor specific cytotoxic t lymphocytes, and plasma cytokine profiles) in the treated patients. * determine the treatment impact on tumor growth (e.g., objective response, time to progression). outline: patients receive b7-dendritic cell cross-linking antibody iv once on day 1. patients undergo peripheral blood collection at baseline and periodically after infusion for analysis of dendritic cell activation, cytotoxic t-lymphocyte activity, immune cell impact, and serum cytokine changes using immunophenotyping and flow cytometry. after completion of study treatment patients are followed every 2 months for 5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed melanoma * stage iv disease (m1a and m1b only) * measurable disease according to recist criteria * hla-a2 positive * must have iga in serum (any concentration) * no known standard therapy for this disease that is potentially curative or proven capable of extending life expectancy patient characteristics: * ecog performance status 0-2 * hemoglobin ≥ 10.0 g/dl * platelet count ≥ 75,000/mm\^3 * ast ≤ 5 times upper limit of normal * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * able to provide informed consent * agrees to return to mayo clinic rochester for follow-up * agrees to participate in the mandatory translational research component of the study * no uncontrolled or current infection * no known immune deficiency * no b or ab blood grouping prior concurrent therapy: * more than 4 weeks since prior chemotherapy and recovered * more than 4 weeks since prior biologic therapy * no concurrent immunosuppressive therapy

Keywords: recurrent melanoma stage iv melanoma
intralesional ranibizumab on pterygium vascularity, size and recurrence rate: a pilot study

Conditions: Pterygium

Summary: the purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

the purpose of this study is to: 1. compare the vascularity of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 ml) injection. 2. compare the size of primary pterygium before and 1 week after intralesional ranibizumab (0.3 mg/0.03 ml) injection. 3. compare the recurrence rate at 1 year after pterygium excision surgery between the group with and without intralesional ranibizumab injection.

Eligibility criteria:
inclusion criteria: * all patients with primary pterygium. * grade t3 (fleshy) pterygium. exclusion criteria: * patients with other ocular surface disorders. * previous ocular surgery or trauma. * history of systemic thromboembolic event. * pregnant women and lactating mother.

Keywords: pterygium ranibizumab anti-vegf recurrence vascularity size
pilot study of metformin in head and neck squamous cell cancer and its effects on stromal-epithelial metabolic uncoupling

Conditions: Head and Neck Squamous Cell Cancer

Summary: the purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease tomm20 expression in squamous carcinoma cells and decrease mct4 expression in fibroblasts.


Eligibility criteria:
inclusion criteria: * diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at tjuh * age ≥ 18 years of age and ≤80 years old. * newly diagnosed with hnscc cancer. * no prior therapy for hnscc cancer is permitted for enrollment in the trial. * all subjects must be able to comprehend and sign a written informed consent document. exclusion criteria: * pregnant or may become pregnant during metformin administration. * on metformin for any reason during the preceding 4 weeks. * diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas. * received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin. these patients cannot start investigational metformin until 48 hours have elapsed from contrast administration. subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded. * plasma alanine aminotransferase greater than 40 iu/dl. * plasma aspartate aminotransferase greater than 45 iu/dl. * plasma creatinine level greater than 1.3 mg/dl. * plasma alkaline phosphatase greater than 190 iu/dl. * plasma bicarbonate less than 22 meq/l or history of lactic or any other metabolic acidosis. * history of congestive heart failure. * myocardial ischemia or peripheral muscle ischemia. * sepsis or severe infection. * history of lung disease currently requiring any pharmacologic or supplemental oxygen treatment. * scheduled for definitive hnscc cancer surgical resection less than two weeks from enrollment or greater than five weeks from enrollment. * history of hepatic dysfunction or hepatic disease. * excessive alcohol intake which is defined in accordance with cdc definitions as more than 1 drink per day for women and more than 2 drinks per day for men. all medications are permitted except those that are contraindicated with metformin under current fda recommendations.
efficacy and safety of calcipotriol cream and (calcipotriol + betamethasone dipropionate) ointment in psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends 3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream the objective is to compare the efficacy and safety of the different treatment regimens

a phase iv study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) ointment following treatment with combination ointment in psoriasis vulgaris

Eligibility criteria:
inclusion criteria: * patients with psoriasis vulgaris of trunk and/or limbs exclusion criteria: -
rct of qps vs general information sheet

Conditions: Advanced Malignant Neoplasm; Caregiver; Physician

Summary: this trial studies how well information materials work in helping communication between physicians and participants with cancer that has spread to other places in the body and their caregivers. approaches that encourage participants to actively participate and ask appropriate questions during their visit may be important to enhance their understanding of their illness and empower them to make important decisions regarding their medical care.

primary objectives: i. to compare patients' perception of helpfulness in communicating with their physicians between a question prompt sheet (qps) and a general information sheet (gis). secondary objectives: i. to compare caregivers' perception of helpfulness in communicating with their physicians between the qps and the gis. ii. to examine the level of patients' and caregivers' overall satisfaction with the consultation with the use of the qps versus the gis. iii. to examine physicians' views about the information material and overall satisfaction with the use of the qps versus the gis. iv. to explore how the use of qps affects the average speaking time of patient or physician during the consultation visit. v. to establish demographic and clinical predictors of patients' perception of helpfulness of a qps. vi. to examine the overall patients' preference between the qps and gis in an open label phase. vii. to compare the change in patient anxiety state with the use of the qps versus the gis. viii. to explore the factors underlying patients' preferences for the qps or gis. outline: participants are randomized into 1 of 2 groups. group i: participants receive qps and answer questions from physician. at follow up visit, participants receive both qps and gis. group ii: participants receive gis and answer questions from physician. at follow up visit, participants receive both qps and gis.

Eligibility criteria:
inclusion criteria: * (patient participation) first outpatient consultation visit with a palliative care specialist * (patient participation) normal cognitive status, defined as a normal state of arousal and an absence of obvious clinical findings of confusion, memory deficits or concentration deficits, as determined by the patient's physician * (patient participation) ability to read and communicate in english * (patient participation) diagnosis of advanced cancer * (patient participation) signed written informed consent form * (caregiver participation) accompanied the patient to the clinic visit * (caregiver participation) is identified by the patient as someone who is actively involved in their overall care * (caregiver participation) is able to read and communicate in english * (caregiver participation) is willing to participate in the study and able to complete the questionnaires * (physician participation) a palliative medicine specialist * (physician participation) seeing the patient in consultation on the day of the study * (physician participation) willing to participate in the study exclusion criteria: * refusal to participate in the study
early verticalization in neuroicu with erigo: a safety and feasibility study

Conditions: Brain Injury

Summary: severe brain injuries induce alteration of state of consciousness. these functional limitations can be significantly alleviated by treatment neurorehabilitation, particularly if this is established early. it has been shown that treatment of vertical integration in patients in a vegetative state or minimally conscious state can improve the level of supervision and positive influence on rehabilitation. therefore, there are sufficient indications that anticipate the treatment of vertical integration, since the phase of hospitalization in icus, may improve the functional outcome of the patient.

early verticalization and stepping with the equipment hocoma erigo, during monitoring of vital parameters. the device erigo is already ce marked and, for the purposes of the study, will be used in accordance with the intended use of the same mark (after-market clinical investigation).

Eligibility criteria:
inclusion criteria: 1. patient / a severe acquired brain injury occurred 3 to 30 days prior to enrollment 2. age between 18 and 75 years 3. glasgow coma scale ≤ 8 at entrance in icus 4. adequate respiratory exchange with pao2/fio2 ≥ 250 5. absence of sedation increased exclusion criteria: 1. major chest trauma with multiple rib fractures and / or pneumothorax 2. presence of fractures, vascular lesions, skin lesions with loss of substance in the abdomen, pelvis or lower limb 3. cardiovascular instability despite support with amines 4. intracranial pressure (icp)\> 25 mm / hg 5. cerebral perfusion pressure (ppc) \<60 mm / hg 6. severe kidney failure requiring replacement therapy 7. decompensated liver disease 8. hematocrit value of ≤ 30% 9. body weight\> 135 kg or height\> 210 cm 10. deep vein thrombosis

Keywords: brain injury coma intensive care early rehabilitation
acupuncture for primary insomnia

Conditions: Insomnia

Summary: this is a randomized controlled trial to evaluate acupuncture treatment on insomnia in the adult population in hong kong.

acupuncture is potential to be an alternative treatment for primary insomnia. the purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on primary insomnia. this is a randomized single-blinded controlled trial. patients will be randomly assigned to the electro-acupuncture group or the placebo acupuncture group. patients will be put into groups and then compared.

Eligibility criteria:
inclusion criteria: * hong kong residents * aged 18-65 * ethnic chinese * meet the diagnosis criteria of primary insomnia for at least 3 months according to dsm-iv using the structured clinical interview for dsm-iv (scid) * willing to give informed consent * total score of insomnia severity index (isi) at least 15 * able to comply with trial protocol exclusion criteria: * participation in any clinical trial during the previous 3 months prior to baseline * any current major depressive disorder, generalized anxiety disorders or panic disorder, manic or hypomanic episode, substance use disorders besides caffeine and nicotine, organic mental disorder, schizophrenia or any other psychotic disorder as defined by dsm-iv criteria * serious physical illness or mental disorders due to a general medical condition which is judged by the investigator to render unsafe * valvular heart defects, bleeding disorders or taking anticoagulant drugs. * any acupuncture treatment during the previous 12 months prior to baseline. * in the investigator's opinion, the patient has a significant risk of suicide * pregnant, breast-feeding, or woman of childbearing potential not using adequate contraception * infection or abscess close to the site of selected acupoints and in the investigator's opinion inclusion is unsafe * herbal remedies, over-the-counter medications or psychotropic drugs, which are intended for insomnia, were taken within the last 2 weeks prior to baseline or during the study

Keywords: insomnia acupuncture electroacupuncture randomized clinical trial traditional chinese medicine